NIH Licenses Gene-Editing Breakthrough to Cure Rare ROSAH Syndrome Vision Loss
Published Date: 3/20/2026
Notice
Summary
The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Potential Vision-Restoring Therapy For ROSAH
Researchers report a gene-editing method that precisely repairs the ALPK1 p.Thr237Met mutation in patient-derived cells with high accuracy and no side effects in lab tests, and the therapy could be delivered to the eye or salivary glands or via corrected patient cells returned to the patient. This technology could, if developed and commercialized, offer personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.
Government Gene-Editing Available for Licensing
The National Institute of Allergy and Infectious Diseases (NIAID) is offering a gene-editing technology that fixes the ALPK1 p.Thr237Met mutation (causing ROSAH syndrome) for licensing to commercial developers under 35 U.S.C. 209 and 37 CFR part 404. Companies interested in commercializing the invention should reference HHS Reference No. E-044-2024-0 when contacting the licensing office.
Agency Seeking Research Collaborators
NIAID is seeking statements of capability or interest from parties for collaborative research to further develop, evaluate, or commercialize this technology, with specific interest in human clinical trials. Parties that want to collaborate should contact David Yang at 240-695-6406 or [email protected].
Patent Filings Extend Market Coverage
Intellectual property associated with this invention includes Provisional Patent Application No. 63/733,836 filed December 13, 2024, and PCT Patent Application No. PCT/US2025/059432 filed December 12, 2025; foreign patent applications have been filed on selected inventions and may be available for licensing to extend market coverage. Reference: HHS Reference No. E-044-2024-0.
Technology Is At Pre-Clinical Stage
The notice states the invention's development stage as "Pre-Clinical," indicating it has laboratory results but has not yet entered human clinical trials. NIAID specifically notes interest in collaborators for human clinical trials to advance development.
Confidentiality Agreement Needed For Details
To receive copies of unpublished information about the invention, interested parties must sign a Confidential Disclosure Agreement (CDA) before NIAID will share full details. Contact David Yang at 240-695-6406 or [email protected] to request information and the CDA.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2026-05526, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 16, 2026, to review and evaluate grant applications and contract proposals. These meetings protect private info and trade secrets, so the public can’t attend. Researchers and organizations applying for funding should note these important review dates as they impact which projects get supported.
Next: 2026-05528, Agency Information Collection Activities; Comment Request; State Workforce Program Certification
The Department of Education wants your thoughts on a new form for State Workforce Programs to certify their info. This helps make sure the government collects only what’s needed without extra hassle. If you’re involved with these programs, you can comment by May 19, 2026—no cost changes, just smoother paperwork!